Evaluation of Heterogeneity in the Coding Region of BRAF , MAP2K1 , and MAP2K2 Genes in Primary and Metastatic Melanomas
- 26 November 2024
- journal article
- research article
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (1) , 48-59
Abstract
Introduction: The incidence of melanoma has been increasing in recent decades. BRAF mutations appear in 50%–70% of melanomas. The BRAF‐targeted therapy increased the disease‐free survival of patients with metastatic melanoma, but this response may be short, due to several resistance mechanisms, such as the presence of other subclones with mutations. Evaluation of mutations and heterogeneity in the coding region of the BRAF , MAP2K1 , and MAP2K2 genes in primary and metastatic melanomas. Patients and Methods: Twenty‐seven samples of primary and metastatic superficial spreading melanoma (SSM) and acral lentiginous melanoma (ALM) were analyzed for BRAF , MAP2K1 , and MAP2K2 mutations using the next‐generation sequencing technique. Results: In ALM, the mutation rate found was 50% in the BRAF and MAP2K1 genes and 28.6% in MAP2K2 . In the SSM, BRAF was mutated in 76.9%, MAP2K1 in 30.8%, and MAP2K2 in 23.2% of the cases. All samples were formed by distinct tumor subclones in the same lesion. Intertumoral heterogeneity was present between primary and metastatic lesions of ALM in BRAF , MAP2K1 , and MAP2K2 ; the cases of SSM were heterogeneous for BRAF and MAP2K1 . Conclusion: We sought to evaluate the mutations in the BRAF, MAP2K1, and MAP2K2 genes, revealing a heterogeneous mutation profile in samples of ALM and SSM.Keywords
Funding Information
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2017/10547‐8)
This publication has 43 references indexed in Scilit:
- From Breslow to BRAF and immunotherapy: evolving concepts in melanoma pathogenesis and disease progression and their implications for changing management over the last 50 yearsHuman Pathology, 2020
- Many ways to resistance: How melanoma cells evade targeted therapiesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2019
- Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilitiesThe Journal of Pathology, 2018
- Discrepancy in BRAF status among patients with metastatic malignant melanoma: A meta-analysisEuropean Journal of Cancer, 2017
- Exomic variants of an elderly cohort of Brazilians in the ABraOM databaseHuman Mutation, 2017
- Prospective Enterprise-Level Molecular Genotyping of a Cohort of Cancer PatientsThe Journal of Molecular Diagnostics, 2014
- Intratumoral Heterogeneity as a Therapy Resistance Mechanism2012
- Acral Lentiginous MelanomaClinics In Laboratory Medicine, 2011
- Improving the Assessment of the Outcome of Nonsynonymous SNVs with a Consensus Deleteriousness Score, CondelThe American Journal of Human Genetics, 2011
- BRAF Signaling and Targeted Therapies in MelanomaHematology/Oncology Clinics of North America, 2009